These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 20027193)

  • 1. Aldosterone and arterial hypertension.
    Tomaschitz A; Pilz S; Ritz E; Obermayer-Pietsch B; Pieber TR
    Nat Rev Endocrinol; 2010 Feb; 6(2):83-93. PubMed ID: 20027193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
    Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forms of mineralocorticoid hypertension.
    Ferrari P; Bonny O
    Vitam Horm; 2003; 66():113-56. PubMed ID: 12852254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart.
    Azibani F; Benard L; Schlossarek S; Merval R; Tournoux F; Fazal L; Polidano E; Launay JM; Carrier L; Chatziantoniou C; Samuel JL; Delcayre C
    Hypertension; 2012 Jun; 59(6):1179-87. PubMed ID: 22547442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Contribution of CYP11B2, REN and AGT genes in genetic predisposition to arterial hypertension associated with hyperaldosteronism].
    Chikhladze NM; Samedova KhF; Sudomoina MA; Thant M; Htut ZM; Litonova GN; Favorov AV; Chazova IE; Favorova OO
    Kardiologiia; 2008; 48(1):37-42. PubMed ID: 18260994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
    Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New genetic insights in familial hyperaldosteronism.
    Jackson RV; Lafferty A; Torpy DJ; Stratakis C
    Ann N Y Acad Sci; 2002 Sep; 970():77-88. PubMed ID: 12381543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative genetic analysis of different forms of low-renin arterial hypertension].
    Chikhladze NM; Samedova KhF; Sudomoina MA; Min K; Koliadina IuA; Litonova GN; Favorov AV; Chazova IE; Favorova OO
    Mol Biol (Mosk); 2008; 42(4):588-98. PubMed ID: 18856058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cytochrome 11B2 aldosterone synthase gene rs1799998 single nucleotide polymorphism determines elevated aldosterone, higher blood pressure, and reduced glomerular filtration, especially in diabetic female patients.
    Sydorchuk L; Dzhuryak V; Sydorchuk A; Levytska S; Petrynych V; Knut R; Kshanovska A; Iftoda O; Tkachuk O; Kyfiak P; Popovich A; Khomko O; Sydorchuk R
    Endocr Regul; 2020 Jul; 54(3):217-226. PubMed ID: 32857720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics of mineralocorticoid excess: an update for clinicians.
    Zennaro MC; Rickard AJ; Boulkroun S
    Eur J Endocrinol; 2013 Jul; 169(1):R15-25. PubMed ID: 23610123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?
    Lim PO; Struthers AD; MacDonald TM
    J Hypertens; 2002 Jan; 20(1):11-5. PubMed ID: 11791020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. -344C/T polymorphism of CYP11B2 gene in Italian patients with idiopathic low renin hypertension.
    Rossi E; Regolisti G; Perazzoli F; Negro A; Davoli S; Nicoli D; Sani C; Casali B
    Am J Hypertens; 2001 Sep; 14(9 Pt 1):934-41. PubMed ID: 11587161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension and the expanding role of aldosterone.
    Mackenzie SM; Connell J
    Curr Hypertens Rep; 2006 Jun; 8(3):255-61. PubMed ID: 17147925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone-related genetic effects in hypertension.
    Warnock DG
    Curr Hypertens Rep; 2000 Jun; 2(3):295-301. PubMed ID: 10981163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system.
    Nishiyama A; Hasegawa K; Diah S; Hitomi H
    J Pharmacol Sci; 2010; 113(4):310-4. PubMed ID: 20675957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are there unknown mineralocorticoids in low-renin essential hypertension?
    Hollifield JW; Slaton PE; Wilson HM; Sennett JA; Yarbro L; Island DP; Liddle GW
    Mayo Clin Proc; 1977 May; 52(5):329-33. PubMed ID: 323587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some considerations about evolution of idiopathic primary aldosteronism.
    Armanini D; Fiore C
    J Endocrinol Invest; 2009 Jul; 32(7):623-5. PubMed ID: 19893360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.